By Longevity Biotechnology Association –
Longevity Biotechnology Association (LBA) held its inaugural Investors Conference on October 23, 2025, in New York City — an event that brought together leading investors, early-stage biotech founders, and scientists advancing therapies that target the biology of aging.
The event convened 9 companies and 15 hand-selected investors. The goal was simple but ambitious: to help bridge the gap between geroscience research and the capital needed to translate it into clinical breakthroughs.
Throughout the day, there was incredible energy in the room, with great conversations, new connections forming, and genuine excitement about how far the longevity biotech field has come. Investors were impressed not only by the science but also by the growing number of companies developing real gerotherapeutics—treatments that target aging itself as the root cause of disease.
This was a powerful proof of concept for what the LBA aims to do:
- -Connect investors with science-driven founders building evidence-based longevity companies.
- -Elevate standards across the field by emphasizing transparency and clinical validation.
- -Build community among those shaping the future of human healthspan.
We’re already planning future events that will expand on this momentum and bring together clinical-stage companies, investors, and global thought leaders to continue building the infrastructure for a credible, thriving longevity biotech ecosystem.
Thank you to everyone who continues to support the mission of the LBA and the broader movement to turn the science of aging into a new frontier of medicine.
NOVOS Chris Mirabile Neurodon LLC Brunde Broady Cellergy Therapeutics Rachel Diamant Vascarta Inc. Richard Prince LyGenesis Michael Hufford Kevin Slawin MD Jim Jenson Amaro Therapeutics, Inc. Christopher Bradley Risa Starr James Peyer, PhD Nir Barzilai
